ArticleMolecular biology reports2026
N-acetylcysteine as an adjunct therapy ameliorates oxidative stress and attenuates anaemia, acute phase response and hepatic injury in clinical Babesia gibsoni infection in dogs-a pilot study.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- From antidote to multimodal adjunct: a systematic review of N-acetylcysteine in dogs and cats.Frontiers in veterinary science · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA prospective, case-controlled and randomized clinical trial was conducted to determine the effect of N-acetylcysteine (NAC) supplementation as an adjunct therapy on haemogram, serum biochemical profile, acute phase response, oxidative stress and clinical score in dogs infected with Babesia gibsoni.
methodsOutpatient dogs showing the clinical manifestations of B. gibsoni infection were randomized to one of the two treatment groups: standard treatment (ST) (n = 12) consisting triple drug therapy of doxycycline, clindamycin and metronidazole along with supportive therapy, and ST with NAC (ST + NAC) (n = 12) at the dose 70 mg/kg, PO, OD for 14 days. The primary outcome measure was reduction of clinical score. Secondary outcome measures were improvement of haemato-biochemical profile, acute phase response, and oxidative stress indices from day 0 to day 28. Haemogram and serum biochemical profile including C-reactive protein (CRP) were determined by automated blood cell counter and biochemical analyser, respectively. Oxidative stress indices like lipid peroxide (LPO), reduced glutathione (GSH) and total antioxidant capacity (T-AOC) were measured using commercially available kits.
resultsThe supplementation of NAC along with ST resulted in early improvement from anaemia, acute phase response, and hepatic injury on day 14 as compared to ST alone. Additionally, NAC supplementation noticeably reduced LPO, and improved GSH and T-AOC on day 14 as compared to ST alone.
conclusionFrom the present study findings, it is concluded that NAC as an adjunct therapy ameliorates oxidative stress and attenuates anaemia, acute phase response and hepatic injury associated with B. gibsoni infection in dogs. Given the small sample size, further large-scale clinical trials are recommended to validate the therapeutic potential of NAC as an adjunct therapy for clinical B. gibsoni infection in dogs.
Indexed as
Identifiers
41838252What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.